Novartis Unveils Direct-to-Patient Platform for Cosentyx
In an exciting development for patients in the United States, Novartis has announced the launch of a direct-to-patient (DTP) platform for their leading product, Cosentyx (secukinumab). This initiative aims to improve access and affordability for patients prescribed Cosentyx, allowing cash-paying individuals to purchase the medication at a 55% discount off the list price.
What is the DTP Platform?
The DTP platform is designed to provide a more straightforward purchasing process for patients, directly connecting them with Novartis and removing barriers typically associated with traditional healthcare pricing. Set to launch on November 1, 2025, this platform will initially focus on Cosentyx, which is well-known for its effectiveness in treating multiple immune-mediated inflammatory diseases, including psoriasis and psoriatic arthritis.
Victor Bultó, President, US for Novartis, emphasized the company’s commitment to innovation, stating, "Breakthrough innovation is what drives us at Novartis, in scientific research, medicine development, and in the ways in which we deliver our innovation to patients." This innovative approach illustrates their endeavor to enhance the healthcare experience for patients across America.
Impact on Patient Access and Affordability
The initiative not only showcases Novartis's commitment to patient care but also sets a precedent for how specialty medicines can be supplied in a more patient-friendly manner. By reflecting the average savings that insurers typically receive, the DTP platform serves as a proof-of-concept for a future model that could reshape how specialty medications are sold.
Furthermore, Novartis is exploring the possibility of extending this model to other suitable products in their portfolio, ensuring that more patients have access to essential medications at reduced costs. There are plans to develop a direct-to-business model, selling Cosentyx and potentially other medications to large employers, aiming to reduce costs and expand access for employees.
Support Programs for Patients
In addition to the DTP platform, Novartis has developed several assistance programs to aid patients in accessing Cosentyx. For those with commercial insurance, there are opportunities to pay as little as $0 for their prescriptions. Eligible patients undergoing the appeals process for coverage denials can receive the medication at no cost for up to two years.
The Novartis Patient Assistance Foundation, Inc. (NPAF) also plays a crucial role in supporting patients who are uninsured or cannot afford their medications. Through this independent non-profit organization, eligible patients may receive Cosentyx free of charge, embodying Novartis's dedication to patient-centric care.
Understanding Cosentyx (secukinumab)
Cosentyx is a fully-human biologic designed to target interleukin-17A, a crucial cytokine implicated in the inflammation associated with various immune-mediated inflammatory diseases. It holds approvals for treating adults with conditions such as psoriatic arthritis, moderate to severe plaque psoriasis, and others.
The drug's long-standing efficacy is supported by over ten years of data demonstrating its safety and effectiveness. Since its market introduction in 2015, more than 1.8 million patients worldwide have benefitted from its use, showcasing its global impact and acceptance. Moreover, it has received approvals in more than 100 countries, underscoring its significance in therapeutic treatment plans.
Committing to Continuous Improvement
Novartis's approach to healthcare is centered around continual improvement and understanding patient needs. The launch of the DTP platform represents an important milestone in this journey, as the company strives for transparency and accessibility within the healthcare system. By directly reaching patients, Novartis not only reinforces its commitment to innovation but also enhances the overall healthcare experience.
This forthcoming shift in medication accessibility highlights Novartis's vision to empower patients, allowing them to obtain the necessary treatments without unnecessary financial strain. The initiative could potentially inspire other pharmaceutical companies to consider similar models, paving the way for a more patient-focused industry.
Frequently Asked Questions
What is the direct-to-patient (DTP) platform?
The DTP platform allows cash-paying patients to buy Cosentyx directly from Novartis at a 55% discount off the list price.
When will the DTP platform be available?
The DTP platform is set to launch in the US on November 1, 2025.
How does the DTP platform affect patient costs?
It significantly reduces costs for patients, making medication more affordable by reflecting the average savings offered to insurers.
Are there assistance programs available for Cosentyx?
Yes, Novartis offers various assistance programs, including potential $0 copays for eligible patients with commercial insurance.
What conditions does Cosentyx treat?
Cosentyx is approved for multiple conditions, including psoriatic arthritis, psoriasis, and other immune-mediated inflammatory diseases.
